Cipher Pharmaceuticals is improving drugs for better results. We are a specialty pharmaceutical company that develops improved formulations of known molecules using drug delivery technologies. Currently, we have three products all of which have been approved by the FDA.
| |
 |
 |
 |
| Indication |
High cholesterol (hyperlipidemia)
|
Moderate to Moderately severe pain (e.g. osteoarthritis)
|
Severe acne
|
|
Delivery technology
|
Oral Lidose® technology
|
Oral controlled release beads
|
Oral Lidose® technology
|
| Benefit |
Enhanced absorption under high fat vs. low fat fed conditions
|
Once-daily dosing provides 24-hour coverage
Rapid absorption and consistent absorption under fed and fasted conditions
|
Significantly more consistent absorption under variable dietary conditions
|
|
Stage of development/
commercialization
|
- U.S. commercial launch in 2007
- Marketed by Kowa Pharmaceuticals America
|
ConZip®
- U.S. commercial launch in Q3 2011
- Marketed by Vertical Pharmaceuticals
Durela®
- Canadian commercial launch in Q1 2012
- Marketed by Medical Futures
|
- FDA approval received May 2012
- U.S. marketing partnership with Ranbaxy Pharmaceuticals
- US commercial launch in Q4 2012 as Absorica™
- Health Canada approval received November 2012.
- To be launched in Canada as Epuris™ in early Q3 2013
|